Cancer

Researchers test a personalized cancer immunotherapy called Cellgram-DC in people with advanced or recurrent epithelial ovarian cancer. The treatment uses a patient's own dendritic cells, a type of immune cell, to try to trigger an immune response against the tumor. Participants …

Researchers are testing a cell therapy called OPC-415 in adults with multiple myeloma that has come back or stopped responding to standard treatments. Participants must have the MMG49 antigen on their cancer cells and have already tried at least two prior regimens. The trial meas…

This study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin, a rare and aggressive cancer with limited treatment options. About 87 partici…

Researchers test whether four cycles of dose-dense MVAC chemotherapy, given with G-CSF support, can shrink or eliminate muscle-invasive bladder cancer before radical surgery. The trial enrolls 24 adults with locally advanced urothelial carcinoma of the bladder who are fit for cis…

Researchers are testing an experimental oral drug called RVU120 in adults with advanced or metastatic solid tumors that have worsened after standard treatments. The trial has two parts: first, they check safety and find the best dose; second, they measure how well the drug shrink…

Researchers are testing RVU120, an experimental oral drug, in adults with acute myeloid leukemia (AML) that has come back or stopped responding to treatment, or with high-risk myelodysplastic syndrome (MDS). The drug blocks two enzymes called CDK8 and CDK19, which may play a role…

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…

Researchers are testing an experimental drug called RVU120 in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or stopped responding to treatment. RVU120 blocks two proteins, CDK8 and CDK19, that may help cancer cells grow. T…

This Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…

Researchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…

This phase II trial is testing whether a combination of two drugs, rigosertib and pembrolizumab, can help people with advanced melanoma that no longer responds to standard immunotherapy. The study involves 7 participants with unresectable or metastatic melanoma. The goal is to se…

This early-phase trial tests whether using MRI scans to guide the placement of internal radiation (brachytherapy) can improve treatment for women with advanced cervical or vaginal cancers linked to HPV. The study involves 26 participants and compares MRI-guided placement to stand…

This study tested giving immunotherapy drugs before surgery to people with liver cancer that could be removed. The goal was to see if these drug combinations could shrink the tumor or eliminate it before the operation. 62 participants took part in this early-phase trial, which ha…

This early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…

This study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…

This phase 3 trial tested a new immunotherapy combination (pembrolizumab plus vibostolimab) with chemotherapy against the standard pembrolizumab-plus-chemotherapy for people with advanced non-small cell lung cancer. The study enrolled 739 participants who had not received prior t…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This early-phase trial tests a new cell therapy called BSB-1001 in 38 adults with high-risk blood cancers (AML, ALL, or MDS) who are getting a stem cell transplant. BSB-1001 is made from donor immune cells that are modified to attack a specific marker on cancer cells. The goal is…

Researchers are testing an experimental daily capsule called AP-L1898 in adults with locally advanced or metastatic non-small cell lung cancer that cannot be treated with chemoradiotherapy. The study enrolls people whose cancer has worsened after standard treatment and whose tumo…

This study tested whether adding the drug alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was stopped early.…

This clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…

This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results ar…

Researchers are testing an experimental drug called MRG003 in adults with advanced gastric or gastroesophageal junction cancer that has spread or cannot be removed by surgery. The trial enrolls people whose tumors test positive for EGFR and negative for HER2, a combination that l…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-stage trial tests whether combining two drugs, INCB099280 and adagrasib, is safe and tolerable for adults with advanced solid tumors that carry a specific genetic change called KRAS G12C. The study enrolls people whose cancer has spread or is locally advanced and who h…

This phase III trial tests whether adding denosumab, a drug often used for bone health, to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 595 adults with advanced disease will receive either chemotherapy alone or chemotherapy plus d…

Researchers are testing whether combining ribociclib and belinostat can help people with metastatic triple-negative breast cancer or recurrent ovarian cancer. The trial starts by finding the safest dose of the drug pair, then expands to see how well it works in breast cancer pati…

This early-phase study tested an investigational drug called MGY825 in 41 adults with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2/KEAP1/CUL3 mutations). The main goal was to check the drug's safety and find the right dose. The study was terminate…

This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up…

This phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enro…

This study tests a new drug (ADI-PEG 20) combined with chemotherapy and radiation before surgery for soft tissue sarcoma. The goal is to find the safest dose and see how well it shrinks tumors. Only 6 patients with intermediate or high-grade sarcoma of the trunk or limbs are taki…

This study tests whether a daily kava drink can help active smokers who don't plan to quit reduce their smoking and lower their risk of lung cancer. Twenty adult smokers will take kava daily for several months. Researchers will check how well participants stick with the regimen, …

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This early-stage trial tests an experimental cell therapy called GAIA-102 in people with advanced or relapsed non-small cell lung cancer. Researchers give GAIA-102 alone or with the immunotherapy drug pembrolizumab to see if the combination is safe and can shrink tumors. The stud…

This Phase 3 trial tests whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer. About 252 participants will receive either the combination or pembrolizumab alone. T…

This phase 2 trial tests whether a 12-week course of docetaxel plus trastuzumab after surgery can keep small (≤1 cm), node-negative HER2-positive breast cancer from returning. Women who have completed radical surgery for this type of cancer receive the two drugs every three weeks…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study looked at whether switching from the immunotherapy durvalumab to the targeted drug sotorasib can better control locally advanced non-small cell lung cancer in patients with a KRAS G12C mutation and signs of remaining cancer (minimal residual disease). Ten participants …

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of the…

This phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The…

This early-phase trial tests whether adding a combination of rintatolimod, celecoxib, and interferon alpha-2b can enhance the effectiveness of pembrolizumab, an immunotherapy drug, in people with metastatic or unresectable triple-negative breast cancer. The combination aims to mo…

This early-phase study tested an experimental drug called BGB-3245 (brimarafenib) in 109 people with advanced solid tumors that had not responded to standard treatments. The drug is designed to block certain proteins that help cancer grow. The main goals were to check safety, fin…

This early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, an…

This phase 2 trial tests whether adding panitumumab to standard chemotherapy can shrink tumors in people with metastatic colorectal cancer that has low-frequency RAS mutations. The idea is that even if a small number of cancer cells have the mutation, most cells may still respond…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This clinical trial is testing whether a combination of two immunotherapy drugs, relatlimab and nivolumab, can help people with advanced colorectal cancer that has not responded to previous treatments. The study compares this combination to two standard chemotherapy options (rego…

This phase 2 trial is testing whether giving two chemotherapy drugs (docetaxel and carboplatin) followed by a maintenance drug called rucaparib can help men with metastatic castration-resistant prostate cancer that has specific DNA repair defects. The idea is that the chemo shrin…

This master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so result…

This phase 2 trial tests two different drug combinations as a first treatment for people with metastatic colorectal cancer—cancer that has spread beyond the colon or rectum. Participants receive capecitabine (Xeloda) plus bevacizumab (Avastin), and are randomly assigned to also g…

This phase 2 trial investigates whether taking the drug sunitinib for one year after surgical removal of lung metastases can improve relapse-free survival in patients with clear cell kidney cancer. Participants are randomly assigned to receive either sunitinib or a placebo follow…

This trial tests a new biologic called CSR02-Fab-TF, given directly into the liver's blood supply, for people with intermediate or limited advanced liver cancer that has not responded to prior treatment. The drug is designed to block blood vessels that feed the tumor while sparin…

This early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This early-phase study tests a new treatment for glioblastoma, an aggressive brain cancer. The approach uses a patient's own immune cells, modified in the lab to better recognize and attack the tumor, combined with chemotherapy. The main goal is to check the safety of this therap…

This trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…

This early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…

This phase II trial is investigating whether adding the experimental drug xevinapant to standard radiation therapy can improve outcomes for adults aged 70 and older with locally advanced head and neck cancer. Participants are randomly assigned to receive either xevinapant or a pl…

This study tests whether a special PET scan (HER2-PET) can help doctors decide which drug to use next in people with advanced HER2-positive breast cancer whose cancer has stopped responding to the drug trastuzumab deruxtecan (T-DXd). About 87 participants will get the scan and be…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…

This phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…

This trial is testing whether the targeted drug pemigatinib can slow or shrink a specific type of bile duct cancer (cholangiocarcinoma) that has a genetic change called FGFR2 rearrangement and cannot be removed by surgery. Participants will receive either pemigatinib as a daily p…

This trial explores whether adding counseling, cognitive behavioural therapy, or hypnotherapy to nicotine replacement therapy can help cancer patients quit smoking before their surgery. The study includes adults with breast, digestive, gynecologic cancer, or melanoma who smoke da…

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…

This trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combin…

This phase 3 trial tests whether metformin, a standard diabetes medication, can prevent or reverse metabolic syndrome in men with prostate cancer who are starting androgen deprivation therapy (ADT). Metabolic syndrome—a cluster of conditions like high blood sugar, high blood pres…

This study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…

This trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-…

This trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only pat…

This phase II study tests two staggered schedules of the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and carboplatin) in 43 adults with advanced non-squamous non-small cell lung cancer. The goal is to see if changing the timing of the drugs impro…

This phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take a…

This trial tests a combination of two drugs, elacestrant and onapristone, in people with a specific type of advanced or metastatic breast cancer that is fueled by the hormones estrogen and progesterone. The goal is to see if blocking both hormone signals at once is safe and can s…

This phase 2 trial tests whether adding metformin — a common diabetes medication — to high-dose dexamethasone can improve outcomes for people with multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults over 18 who have failed at lea…

This phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…

This Phase 3 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can help people with advanced colorectal cancer that can't be removed by surgery and has stopped responding to chemotherapy. About 834 participants will receive either th…

This study tests a 4-week prehabilitation program combining exercise, nutritional supplements, and psychological support for patients with sarcopenia (muscle loss) who are about to have pancreatic cancer surgery. The goal is to see if this program reduces serious complications li…

This early-phase trial tests a new treatment for children and young adults with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment involves taking a patient's own immune cells (T cells), genetically modifying them in the lab to recognize …

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

This study looked at 124 adults with chronic myeloid leukemia (CML) who had been on the drug nilotinib for at least 3 years and had very low levels of cancer. First, researchers tested if lowering the nilotinib dose by half for a year could help patients stop treatment entirely. …

This study tested a daily oral drug called sotorasib in 42 adults with advanced (stage IV) non-small cell lung cancer that has a specific KRAS G12C mutation and has not been treated before. The goal was to see how well the drug shrinks tumors and how safe it is. Participants rece…

This study looks at genetic changes in postmenopausal women with a common type of advanced breast cancer (HR+ HER2-). Participants first receive ribociclib plus letrozole; those with a specific mutation (PIK3CA) may later switch to alpelisib plus fulvestrant. The goal is to track…

This early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so res…

This trial tests whether adding a precise, internal radiation treatment (166Holmium microspheres) to standard immunotherapy (atezolizumab and bevacizumab) can shrink liver tumors that cannot be surgically removed. About 10 adults with unresectable hepatocellular carcinoma will re…

This phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumo…

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…

This study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) given before and after a procedure called electroporation for people with advanced hepatocellular carcinoma (liver cancer) that could still be treated with curative intent. The study aimed to see if adding nivolu…

This early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the d…

This trial tested a vaccine called PD1-Vaxx given before surgery to people with a specific type of colorectal cancer (MSI-high). The goal was to see if the vaccine could shrink tumors, measured by how many cancer cells remained after treatment. Only 3 people took part, and the st…

This phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This phase 3 study tested whether adding canakinumab (an anti-inflammatory drug) to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer. The trial enrolled 673 participants but was terminated early, so the…

This study aimed to compare two standard treatments for people with large intermediate-stage liver cancer that cannot be surgically removed. One group would receive a combination of two immunotherapy drugs (atezolizumab and bevacizumab), while the other would receive local treatm…

This study tests a new treatment called Temferon for people with glioblastoma, a fast-growing brain cancer. The therapy uses a patient's own blood stem cells, modified to deliver interferon directly to the tumor. Up to 27 patients with a specific genetic marker (unmethylated MGMT…

This study tested two different proton therapy schedules for people with large choroidal melanomas (eye cancer) that would normally require removal of the eye. The goal was to see if a gentler radiation schedule could control the tumor and avoid severe side effects, allowing pati…

This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results ar…

This study tested whether applying 0.25% timolol gel (a beta-blocker eye drop used for glaucoma) to skin grafts could improve healing and appearance after skin cancer surgery. Researchers planned to enroll 82 patients but stopped early with only 10 participants. The goal was to s…

This study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…

This phase 3 trial tests whether adding the chemotherapy drug carboplatin to standard palliative radiotherapy helps control tumor growth and reduce pain better than radiotherapy alone. The study includes adults with advanced lung or head and neck cancer who need palliative radiat…

This study tested whether adding venetoclax and azacitidine after a stem cell transplant could help people with acute myeloid leukemia (AML) live longer. It included adults and teens who had recently received a transplant. The trial was stopped early, so the full benefits and ris…

This study tested a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and immunotherapy. The goal was to see if…

This early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was sa…

This study tested whether focused ultrasound could partially destroy a rare soft-tissue cancer called undifferentiated pleomorphic sarcoma and boost the body's immune response. Only 5 people were enrolled before the trial was terminated. The main goal was to check safety and see …

This study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…

This phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage a…

This phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cance…

This study aimed to see if a mistletoe extract placed directly into the bladder could delay cancer return better than standard chemotherapy in 174 people with early-stage bladder cancer. The trial was stopped early, so results are limited. The approach focuses on controlling the …

This study aimed to see if a procedure called angiographic embolization (blocking blood vessels feeding spine tumors) before surgery could reduce blood loss during the operation. It included adults aged 18-75 with spine metastases that had moderate blood supply. The study was sto…

This study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…

This phase 3 trial compared an experimental drug called tusamitamab ravtansine to the chemotherapy docetaxel in 389 people with advanced non-small cell lung cancer that had a specific marker (CEACAM5). The study aimed to see if the new drug could slow cancer growth or improve sur…

This study tested a drug called BM7PE immunotoxin in 14 people with colorectal cancer that had spread and was no longer responding to standard chemotherapy. The goal was to find a safe dose and see if it could help patients live longer. The study was stopped early, so we have lim…

This study tested a treatment called radioembolization for elderly or frail patients whose colorectal cancer has spread only to the liver and cannot be removed by surgery. Instead of standard chemotherapy, tiny radioactive beads are injected into the liver's blood supply to targe…

This study tested a combination of two drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in elderly patients (65 and older) whose multiple myeloma had returned after previous treatments. The goal was to see if this gentler approach could effectively control …

This early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so r…

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

This study tested several immunotherapy-based drug combinations in people with metastatic non-small cell lung cancer. It included two groups: those who had not received prior treatment and those whose cancer had worsened after standard therapy. The trial was terminated early, so …

This study tested a new type of temporary colostomy (a surgical opening in the belly) for people having rectal cancer surgery. The goal was to see if it could reduce bowel problems and kidney injury compared to the usual stoma. Only 16 patients were enrolled before the study was …

This study tested a personalized mRNA vaccine (mRNA-4157) combined with the immunotherapy drug pembrolizumab for people with advanced but removable skin cancer (cutaneous squamous cell carcinoma). The goal was to see if the combination could prevent the cancer from coming back be…

This study tested whether adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) is safe and helps the immune system fight advanced non-small cell lung cancer. It included 19 people with newly diagnosed metastatic lung cancer who had …

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…

This study tested a new type of radiation therapy that adapts daily to the patient's anatomy, combined with chemotherapy, for muscle-invasive bladder cancer. The goal was to see if this approach could lower severe bowel and bladder side effects compared to standard radiation. How…

This early-phase study tested whether a personalized vaccine made from a child's own tumor could train their immune system to fight high-grade gliomas. The treatment involved giving back activated immune cells (T-cells) and dendritic cell vaccines after chemotherapy. Only 5 child…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This early-phase trial tested a combination of two oral drugs, BKM120 and lapatinib, in 24 people with HER2-positive breast cancer that had stopped responding to trastuzumab. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated…

This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. Th…

This early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…

This phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This phase 3 trial tested a new drug, abelacimab, against a standard blood thinner (dalteparin) to prevent dangerous blood clots from returning in people with gastrointestinal or genitourinary cancers. The study enrolled 417 adults with advanced cancer and a recent clot. It was t…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This phase 3 trial tested two types of radiation therapy for glioblastoma, a fast-growing brain tumor. One group received standard 3D radiation, while the other got a more precise intensity-modulated radiation guided by MRI scans. Both groups also took the chemotherapy drug temoz…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…

This phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe do…

This study aimed to compare two different ways of giving chemotherapy (FLOT) to people with stomach or gastroesophageal junction cancer. One group received all chemotherapy before surgery, while the other received some before and some after surgery. The study was stopped early af…

This study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…

This phase 2 trial aimed to see if trastuzumab deruxtecan (Enhertu) could help people with HER2-positive breast cancer that had spread and did not respond to standard first-line therapy. Only 2 participants were enrolled before the study was terminated early, so the results are v…

This early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…

This study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …

This early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…

This phase 2 trial tested the drug lenalidomide in 12 people with HIV who had Kaposi sarcoma, a type of cancer. Participants took lenalidomide pills for 21 days each month. The study aimed to see if the drug could shrink tumors, but it was stopped early, so the results are not co…

This study tested the drug cabozantinib in children, teens, and young adults with osteosarcoma (a bone cancer) that could not be fully removed by surgery. Participants who had stable or partially improved disease after chemotherapy received either cabozantinib plus best supportiv…

This early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…

This study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…

This phase 2 trial tested a liver-directed chemotherapy using idarubicin mixed with lipiodol (a fatty contrast agent) injected directly into the liver artery. The goal was to see if this could control non-spreading liver cancer in 44 patients with cirrhosis. The study was termina…

This study tested whether a nutritional drink called Impact Oral®, taken for 5 days before and after surgery, could reduce complications in colorectal cancer patients. The trial included 71 patients eligible for minimally invasive surgery. However, the study was terminated early,…

This study tested an experimental drug called enfortumab vedotin, alone or with other cancer drugs, in people with advanced bladder or urinary tract cancer. The goal was to see if the drug could shrink tumors and control the disease. The trial included 348 participants but was te…

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the ri…

This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…

This study tested a temporary biodegradable balloon placed between the prostate and rectum during radiation therapy for intermediate-risk prostate cancer. The goal was to see if the balloon could reduce radiation damage to the rectum by pushing it away from the prostate. The stud…

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…

This study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …

This phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) helps people with advanced kidney cancer whose disease worsened after prior immunotherapy. The trial enrolled 522 participants but was terminated early, so the full benef…

This early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…

This study tested whether giving a targeted radiation drug (LuPSMA) with or without an immunotherapy drug (ipilimumab) before prostate removal surgery is safe and feasible for men with very high-risk prostate cancer. Only one participant was enrolled before the study was stopped …

This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…

This phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclea…

This study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…

This phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…

This trial tested a personalized approach for children with relapsed or hard-to-treat neuroblastoma. Doctors used a tumor biopsy to find genetic changes and then assigned a combination of targeted drugs (ceritinib and ribociclib) to match those changes. The study was terminated e…

This phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …

This study tested two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and keep cancer from coming back after. …

This study looked at whether a structured smoking cessation program starting four weeks before surgery could reduce complications in smokers undergoing intermediate to high-risk operations. Researchers planned to enroll 251 adult smokers scheduled for surgeries like abdominal, th…

This study tested a new drug called amcenestrant against standard hormone therapies in 367 people with advanced ER+/HER2- breast cancer. The goal was to see if it could slow cancer growth better than current options. The trial was stopped early, but results help guide future trea…

This phase 2 trial aimed to see if the drug niraparib could shrink tumors in people with metastatic pancreatic cancer that has certain gene mutations. Only 2 patients were enrolled before the study was terminated early, so we don't have enough information to know if it works. The…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early study tested combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug pembrolizumab (Keytruda) in 13 people with metastatic breast cancer. The goal was to see if the ultrasound could help the immune system better recognize and attack tumors. The t…

This study tested a one-time gene therapy called Temferon in 10 people with advanced kidney cancer that had worsened after standard treatments. The goal was to see if it was safe and could activate the immune system against tumors. The trial was terminated early, so results are l…

This early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…

This early-phase trial tested the drug pembrolizumab (Keytruda) combined with targeted radiation (SBRT) in 5 people with advanced malignant pleural mesothelioma, a rare cancer of the lung lining. The goal was to check safety and find the right dose. The study was terminated early…

This Phase 2 trial tested whether adding danvatirsen to the standard immunotherapy pembrolizumab helps people with recurrent or metastatic head and neck squamous cell carcinoma. About 69 adults with PD-L1 positive tumors were randomly assigned to receive the combination or pembro…

This early-phase study tested a new drug called modakafusp alfa combined with daratumumab in 15 people with multiple myeloma that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose. The trial was terminated early, so full…

This early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…

This study tested a treatment for prostate cancer that came back after previous radiation. It combined temporary radioactive implants placed in the prostate, daily external radiation to the pelvis for 5 weeks, and 6 months of hormone therapy. The goal was to see if this approach …

This study looked at whether adding radiation to the chest could improve survival for people with extensive-stage small-cell lung cancer who were already receiving chemotherapy and immunotherapy. The trial planned to enroll 239 participants but was terminated early. The main goal…

This study tested a new drug called modakafusp alfa in 272 people with multiple myeloma that had returned or stopped responding to other treatments. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, but researchers collected dat…

This early-stage trial tested a new drug called modakafusp alfa (TAK-573) combined with standard myeloma treatments in 15 adults with multiple myeloma. The main goal was to check safety and find the best dose. The study was terminated early, so we have limited information on how …

This early-phase trial tested the combination of the immunotherapy drug pembrolizumab (Keytruda) with precise, high-dose radiation (SBRT) in patients with advanced non-small cell lung cancer that had progressed after chemotherapy. The study aimed to find the safest radiation dose…

This Phase 2 trial tested a combination of chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy (IL-12) in 8 women with triple negative breast cancer that had stopped responding to standard anthracycline treatment. The goal was to see if the combina…

This early-stage trial tested a drug called AZD1390, which blocks DNA repair, given with or without an immunotherapy (durvalumab) plus standard radiation before surgery for soft tissue sarcoma. The goal was to see if the combination is safe and tolerable, especially regarding wou…

This study tested whether a special CT scan that highlights blood flow (porto-scanner with Angio-CT) helps doctors more accurately destroy small liver tumors from colorectal cancer using heat ablation, compared to a standard CT scan. The goal was to see if the new method leads to…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve r…

This study tested whether adding sabatolimab to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2). The trial aimed to see if the combination improved survival. However, the study was stopped early, so we …

This phase 2 trial tested whether giving the immunotherapy drug atezolizumab (Tecentriq) alone for two weeks before starting standard chemotherapy could improve outcomes for people with triple-negative breast cancer. The study enrolled 442 participants and compared the two-week w…

This early-phase study tested a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia that returned or didn't respond to standard treatments. The therapy used the patient's own immune cells, modified to target two markers (CD19 and CD20) on leukemi…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced non-small cell lung cancer that had spread. The goal was to see if these drugs could control the cancer without needing chemotherapy. Only 5 people took part before the study was stopped …

This study looked at whether women with a certain type of early-stage breast cancer (HER2-positive, low-risk) could avoid surgery if their tumors completely disappeared after standard drug treatment. Only 5 women enrolled before the study was stopped. The goal was to see if a spe…

This phase 2 study tested a two-step treatment for colorectal cancer that had spread only to the liver and could not be removed by surgery. First, patients received radioactive beads (Holmium-166 TARE) directly into the liver, followed by maintenance chemotherapy and targeted dru…

This study looked at whether a donor stem cell transplant (allogeneic) works better than standard drug therapy for people with multiple myeloma that came back after initial treatment. It included adults aged 18-70 with a compatible donor. The trial was stopped early, so results a…

This study tested a new drug called PLX038 in 14 people with advanced triple-negative breast cancer that had already been treated. The goal was to see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated e…

This phase 2 trial tested the drug pemigatinib in people with recurrent glioblastoma or other brain tumors that have specific changes in FGFR1-3 genes. Participants took a daily tablet for two weeks followed by one week off. The study aimed to see if the drug could shrink tumors,…

This study tested whether adding a short course of focused radiation to standard chemotherapy before surgery could improve outcomes for women with aggressive breast cancers. The trial enrolled 362 patients with luminal B or triple-negative breast cancer that was too large for ini…

This study tested a combination of two drugs, HBI-8000 and pembrolizumab (Keytruda), in people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was stopped early after enrolling only 5 participan…

This study tested whether adding surgery to chemotherapy helps people with stage IV stomach cancer that has spread to only one other area. The goal was to see if surgery could improve survival and quality of life. However, the trial was stopped early after enrolling only 6 partic…

This study tested whether adding a drug called ATRA (all-trans retinoic acid) to the standard hormone therapy anastrozole could shrink tumors more effectively in postmenopausal women with a common type of early breast cancer (HR-positive/HER2-negative). The trial was planned for …

This study tested an experimental drug called THOR-707 in adults with advanced solid tumors that had spread. The goal was to find safe doses and see if the drug could shrink tumors when used alone or with other treatments. The study was stopped early, so results are limited.

This study tested a peptide-based immunotherapy in 17 people with head and neck cancer who were scheduled for surgery. The goal was to see if the vaccine could boost the immune system's attack on cancer cells and to check for side effects. The trial was stopped early, but the res…

This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells…

This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung tumors enough to allow patients to then receive radiation therapy. The trial was stopped early after enrolling only 10 people, so results are limited. The…

This early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest …

This study tested a combination of three drugs—tucatinib, trastuzumab, and vinorelbine—in 13 people with HER2-positive breast cancer that had spread or could not be surgically removed. The goal was to see how many patients' tumors shrank or disappeared. The trial was terminated e…

This study looked at whether giving well-nourished people with gastrointestinal cancer a special nutrition drink for 3 days before surgery could reduce complications and shorten hospital stays. The trial was stopped early, so results are limited. It involved 107 adults with stoma…

This study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminat…

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumor…

This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This study tested a new oral drug called amcenestrant for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The goal was to find safe doses and see if it works alone or with other drugs. The trial was stopped early, but the results help researchers u…

This early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…

This phase 2 trial tested the drug pacritinib in 6 men whose prostate cancer had come back after surgery or radiation, shown by rising PSA levels. The goal was to see if the drug could delay further cancer growth. However, the study was terminated early, so we have limited inform…

This study tested a drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early, so results are limited.

This study compared two procedures for removing early-stage rectal cancer or precancerous growths: endoscopic submucosal dissection (ESD) and transanal endoscopic microsurgery (TEM). Both are less invasive than traditional surgery. The goal was to see which one removes the tumor …

This trial tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. The study was stopped early because of unexpected safety problems that reappeare…

This study looked at whether giving chemotherapy and radiation before surgery could help control glioblastoma, a fast-growing brain tumor. Only 2 people enrolled before the study was stopped. The goal was to see if this approach was safe and could delay tumor regrowth.

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …

This study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…

This study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was terminated earl…

This study tested the drug TAS-102 (also known as Lonsurf) in 14 people with a rare and aggressive type of neuroendocrine cancer that started outside the lungs. The goal was to see if the drug could shrink tumors or improve survival. The trial was stopped early, so results are li…

This phase 2 study tested several drug combinations (retifanlimab, epacadostat, INCAGN02385, INCAGN02390) given before bladder removal surgery in 30 patients with muscle-invasive bladder cancer who could not take the standard chemo drug cisplatin. The trial was terminated early, …

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…

This study tested a treatment called MT-401, which uses specially trained immune cells from a donor to fight acute myeloid leukemia (AML) after a stem cell transplant. The goal was to see if these cells could prevent or treat relapse. The trial enrolled 92 people but was stopped …

This study tested a new drug (tusamitamab ravtansine) combined with pembrolizumab and chemotherapy in 57 people with advanced non-squamous non-small-cell lung cancer that has a specific marker (CEACAM5). The goal was to see if the combination was safe and shrank tumors. The trial…

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

This early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…

This study tested a daily pill called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to see if it was safe and could raise red blood cell levels, reducing the need for transfusions. The trial was terminated early afte…

This study looked at menopausal women over 50 with very small breast cancers (less than 10 mm). It compared standard surgery plus armpit lymph node removal versus surgery alone to see if skipping the extra procedure was safe. The goal was to reduce side effects like arm swelling …

This study tested the drug capmatinib in people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). The goal was to see if taking the drug before and after surgery could improve outcomes. However, the trial was stopped early after enroll…

This study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed …

This phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meani…

This study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial enrolled 247 adults who had not received prior treatment or whose cancer had…

This trial tested whether adding gemcitabine to standard cisplatin and radiation therapy could help control muscle-invasive bladder cancer while preserving the bladder. About 69 patients were enrolled to compare the combination against standard treatment. The study was terminated…

This early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…

This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The trial aimed to see if the combo could shrink tumors or stop them from growing. It included 115 participants but was termi…

This study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…

This phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…

This phase 2 trial tested a combination of a therapeutic vaccine (EO2040) and an immunotherapy drug (nivolumab) in colorectal cancer patients who had minimal residual disease detected by a blood test after completing standard treatment. The goal was to clear remaining cancer cell…

This study tested a precise type of proton radiation (IMPT) for people whose rectal cancer came back after prior radiation. The goal was to find the highest safe dose without causing severe side effects. The trial enrolled 15 adults and was terminated early.

This early trial tested the safety and effectiveness of radioactive beads (Holmium-166 microspheres) in 4 adults with liver cancer that could not be removed by surgery or transplant. Participants first received a small scout dose to check for proper placement, then a personalized…

This phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminate…

This Phase 2 study tested two doses of amcenestrant, a new oral drug that blocks estrogen receptors, against letrozole, a standard hormone therapy, in 105 postmenopausal women with ER-positive, HER2-negative breast cancer. The goal was to see if amcenestrant could better reduce t…

This phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…

This early-phase trial tested a new way to deliver chemotherapy directly to liver tumors that spread from colorectal cancer. Doctors used balloon catheters to isolate the liver's blood supply and then infused oxaliplatin, along with oral capecitabine. Only 5 people took part befo…

This trial compared a newer, robotic-assisted minimally invasive surgery (RAMIE) to the standard open surgery for esophageal cancer. The goal was to see if it's possible to run a larger study comparing the two approaches. The study enrolled 24 adults with stage I-III esophageal c…

This study aimed to see if a new drug called amcenestrant could help prevent breast cancer from coming back in people with hormone receptor-positive early breast cancer who had side effects from standard aromatase inhibitor therapy. It was designed to compare amcenestrant against…

This early-phase trial tested the safety of giving a precise form of radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with metastatic non-small cell lung cancer. The goal was to see if the combination caused severe side effects and whether…

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This phase 3 trial tested whether a new drug called amcenestrant (which blocks estrogen) combined with palbociclib could help people with advanced ER+/HER2- breast cancer live longer without their cancer growing. Over 1,000 participants who had not yet received treatment for adva…

This early-phase trial tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received the drug as a continuous 28-day IV infusion. The study aimed to find the safest dose and check …

This trial tested the drug isatuximab, a targeted antibody, combined with standard chemotherapy in children aged 28 days to under 18 years whose acute leukemia had returned or stopped responding to treatment. The study aimed to see if the combination could help more children achi…

This phase 2 trial tested whether adding trilaciclib (Cosela) to standard chemotherapy and avelumab could help people with advanced bladder cancer by protecting their bone marrow. The study enrolled 92 adults with untreated, locally advanced or metastatic urothelial carcinoma. Un…

This phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…

This study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated e…

This study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer that had returned after standard treatments. The trial aimed to see if VAL-083 could help patients live longer. However, the study was stopped early after only 2 people enrolled, s…

Researchers are testing a breathing sensor called SPI that synchronizes PET/CT scans with a patient's breath. The goal is to see if this device can produce clearer images of lung tumors and nodules. Each participant undergoes a scan with both the SPI device and a standard breathi…

Researchers are testing a nonlinear microscope (NLM) that images breast tissue during lumpectomy without the usual slide preparation. The goal is to see if the NLM can help surgeons find close or positive margins right away, so fewer patients need a second operation. The trial en…

This study tested a dye called tozuleristide that makes oral cancer cells glow under special light during surgery. The goal was to help surgeons see and remove all cancer while sparing healthy tissue. The trial included 8 adults with oral cavity cancer or high-grade dysplasia. Th…

This study tested a smartphone app called CRADLE that uses a photo to detect leukocoria (a white glow in the pupil), which can be a sign of retinoblastoma, cataracts, or glaucoma. Researchers planned to compare the app's accuracy to a standard eye exam in children with these cond…

This early-stage trial tests a radioactive imaging agent called [111In]-FPI-2107 in 12 Chinese adults with EGFR-mutant non-small cell lung cancer. The goal is to see if it is safe and can help detect tumors on SPECT scans. Participants receive the agent plus an unlabelled antibod…

This study looks at whether a special ECG and a blood test can find early signs of heart weakness in adult cancer survivors who had certain chemotherapy. Researchers will check how well these tests work compared to standard heart imaging. The goal is to gather information needed …

This study tested whether a special ultrasound technique (D-CEUS) can predict how well rectal cancer responds to chemotherapy and radiation. The goal is to identify good responders who might avoid major surgery and instead have a less invasive procedure. Only 2 people took part, …

This study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better th…

This trial investigates whether a new, ultra-high-frequency ultrasound device can accurately measure the depth of skin melanomas before surgery. Currently, doctors must remove the tumor, measure its depth under a microscope, and then often perform a second surgery to remove more …

This study tested a new way to guide prostate biopsies by combining three imaging methods: a PET scan using a special tracer (fluorocholine), multiparametric MRI, and 3D ultrasound. The goal was to see if this triple approach could more accurately target suspicious areas in the p…

This study tested whether a special type of PET/CT scan, called PSMA PET/CT, can better detect if prostate cancer has spread to nearby lymph nodes before surgery. The scan uses a radioactive tracer that sticks to prostate cancer cells, making them visible. The goal was to help do…

This study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…

This Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…

This study looked at whether analyzing sputum (phlegm) with automated cytometry, combined with low-dose CT scans and blood tests, could better detect lung cancer in workers heavily exposed to asbestos. The goal was to reduce false positives and improve early diagnosis. The trial …

This study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the…

This pilot study tested a blood-based test (Harbinger test) to help decide who needs a colonoscopy after a positive colorectal cancer screening. The goal was to see if the blood test could accurately predict colorectal cancer or advanced adenomas. However, the study was terminate…

This study tested whether a special imaging technique called narrow band imaging (NBI) can help surgeons find early cancer spots in the mouth that are not visible under normal light. The trial involved 23 people with oral cancer who were already scheduled for surgery. Doctors com…

This study tested a special PET/CT scan that uses a radioactive tracer to see PD-L1 (a protein targeted by immunotherapy) throughout the body. The goal was to see if this scan could better identify which patients with metastatic triple-negative breast cancer would benefit from im…

This study tested whether a special type of MRI called DWIBS can better identify suspicious breast lesions found on mammograms and ultrasounds. The goal was to see if it could accurately tell benign from malignant lesions and potentially reduce false-positive biopsies. Only 11 wo…

This study tested a new imaging device called cCeLL-Ex vivo that uses laser microscopy to quickly detect brain tumors during surgery. The goal was to see if it could diagnose tumors faster than the standard frozen section method, which takes 20-30 minutes. The study enrolled 285 …

This study looked at whether giving radiation to the brain could prevent cancer from spreading there in people with HER2-positive breast cancer that had already spread to other organs. Participants were receiving trastuzumab (Herceptin) plus chemotherapy. The study was stopped ea…

This trial tests whether taking aspirin daily can prevent HER2-negative breast cancer from returning in people who have already had surgery, chemotherapy, or radiation. Participants have node-positive or high-risk node-negative breast cancer and are free of recurrence. Half recei…

This study aimed to see if a tamoxifen skin gel could work as well as the pill to lower breast cancer risk in women with certain high-risk breast conditions. The trial enrolled 65 women and compared short-term changes in breast tissue. However, the study was terminated early, so …

This study looked at whether the drug pregabalin could prevent persistent pain in women at high risk after breast cancer surgery. It included 126 patients who were given either pregabalin or a placebo before and after surgery. The trial was stopped early, and the results did not …

This study looked at whether doing pelvic floor exercises with biofeedback before rectal cancer surgery could prevent a condition called Low Anterior Resection Syndrome (LARS), which causes bowel control problems like leakage and urgency. The study planned to include 120 adults a…

Researchers are testing a synbiotic formula called BLHK03 to see if it can reduce hair loss caused by chemotherapy in women with breast cancer. The trial includes 7 women with stage I to III breast cancer who are scheduled for chemotherapy with anthracycline or taxane drugs. Part…

This study tested whether a single, highly focused dose of radiation to a tiny part of the brain (the pituitary gland) could help relieve severe, hard-to-treat bone pain caused by cancer that has spread. Only 5 people took part, and the study was stopped early. The goal was to se…

This pilot study tests whether a wearable EEG headband (MUSE-S) that guides meditation can help breast cancer survivors who struggle with anxiety and insomnia. Twenty participants will use the headband at home, and researchers will track how often they use it and whether it impro…

This study compared two standard drugs—olanzapine and dexamethasone—for preventing nausea and vomiting caused by chemotherapy. Researchers wanted to see if olanzapine could work as well as the steroid dexamethasone, potentially allowing patients to avoid steroid side effects. The…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can reduce common side effects like rash, diarrhea, and fatigue in cancer patients receiving immunotherapy. Ten adults with advanced cancer will follow the diet and report their symptoms. The goa…

This study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…

This study is testing whether giving women with early-stage breast cancer two easy-to-read booklets can help lower their anxiety after diagnosis. The booklets explain the disease and treatments in a gentle, clear way. About 60 women will take part, and researchers will measure ho…

This study tested a drug called solriamfetol to see if it could safely help people with brain tumors (gliomas) feel more awake, think clearer, and have a better quality of life. Only 2 people enrolled before the study was stopped early. The main goal was to check for serious side…

This study aimed to see if a smartphone app called IONA Mind could help treat depression in people who have had head and neck cancer. Participants would use the app for 6 weeks and fill out surveys. However, the trial was terminated early after enrolling only 1 person, so no mean…

This phase II trial tested whether Swedish massage can reduce fatigue in men who have had radiation for prostate cancer. The study enrolled 28 men aged 45 and older who reported significant fatigue. Researchers measured fatigue levels and inflammatory markers before and after mas…

This study investigates whether giving patients personalized, secure access to a web platform with an explanatory video about their upcoming breast cancer surgery can lower their anxiety. Participants are women with breast cancer scheduled for lumpectomy, oncoplasty, or mastectom…

This study tests a program where older adults with advanced cancer and their caregivers talk about their lives together. The goal is to see if this approach is practical and helps improve emotional well-being and relationship quality. About 60 patient-caregiver pairs will be rand…

This study tested a smartphone app called 'Bouge' to see if it could help women with non-metastatic breast cancer increase their daily steps while on weekly Taxol chemotherapy. The goal was to add 3,000 steps per day over 90 days. Only 23 people enrolled, and the trial was stoppe…

This study looked at whether adding an ultrasound-guided ESP nerve block to standard pain medicine could reduce opioid use and improve pain control after laparoscopic kidney removal for cancer. Ten adults having keyhole kidney surgery were enrolled. The study was stopped early, s…

This study looked at whether a supervised exercise program could help improve quality of life and reduce fatigue in people under 65 with multiple myeloma who had a stem cell transplant. Participants were randomly assigned to either an exercise group or a control group. The study …

This pilot study tested a mouthwash made with homoeriodictyol sodium to reduce bitter taste caused by chemotherapy in women with gynecologic cancers. The study aimed to see if the mouthwash could improve taste and food intake. Only 15 participants were enrolled, and the trial was…

This study looked at whether a supervised exercise program is possible for people with advanced bronchial cancer or mesothelioma. The goal was to see if patients could complete at least 6 rehab sessions to help with weakness and poor quality of life caused by the disease and its …

This study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it reduces hot flashes and night sweats in women with breast cancer taking hormone therapy. Nine participants were enrolled before the trial was stopped early. The goal …

This study looked at men with low or intermediate-risk prostate cancer to see if 2 MRI-guided radiation treatments cause fewer bowel and bladder side effects than 5 treatments. The goal was to find a shorter treatment plan that is just as safe and less bothersome. The study was s…

This study compared two types of radiation therapy given before surgery for locally advanced rectal cancer. The goal was to see if a newer technique called IMRT causes fewer bowel side effects than the standard 3-D conformal radiotherapy. The trial enrolled 94 patients but was te…

This study looked at whether a mechanical stimulation technique can reduce pain and improve shoulder mobility better than standard massage in women who had a total mastectomy with lymph node removal. About 80 participants were planned, all needing physiotherapy after surgery. The…

This study tested whether early, personalized support from a psychologist could help women with breast cancer return to work more successfully than standard support. The study included 128 women who had surgery and chemotherapy. Unfortunately, the trial was stopped early, so we h…

This study tested a morphine gel applied directly to painful mouth sores caused by chemotherapy. The goal was to see if the gel could relieve pain better than morphine given through an IV. The study included children and young adults aged 5 to 25. The gel was applied four times a…

This Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…

This study looked at whether a supplement called Q-Urol (made from quercetin, bromelain, rye flower pollen, and papain) could reduce prostate inflammation caused by radiation therapy in men with localized prostate cancer. Ten men who had brachytherapy (with or without other radia…

This study tested two educational programs for parents with late-stage cancer who have children aged 5 to 17. The programs were designed to improve parent-child relationships and boost parents' confidence in talking about cancer with their kids. Researchers hoped to reduce anxiet…

This study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-bei…

This study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program involved exercises to retrain the nose and tongue. Only 5 people enrolled before the study ende…

This study compared two devices used to collect tissue from the cervix during screening for cervical cancer: the standard Kevorkian curette and a softer cytobrush. The goal was to see if the cytobrush causes less pain while still getting enough cells for diagnosis. Only 3 women w…

This phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the …

This study tested whether a digital health app (Roche DPM Module) helps cancer patients manage symptoms and reduce healthcare visits while on systemic treatment. About 49 participants used the app alongside standard care. The trial was terminated early, so results are limited.

This study tested whether wearing a special chest bandage after mastectomy could reduce the number of times doctors need to drain fluid buildup (seroma). Half of the 60 participants got the bandage plus standard drainage, while the other half had only drainage. The study was stop…

This study tested whether a special oral care routine (dental cleaning and mouth treatment) could reduce severe mouth sores in people getting radiation for head and neck cancer. About 60 adults were planned to join, but the study was stopped early. The goal was to see if this app…

This study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. Ho…

Researchers at Pennington Biomedical Research Center are studying how unintended weight loss affects the way the body burns fuel in people with advanced non-small-cell lung cancer. Participants eat a liquid mixed meal while researchers measure their breathing to see whether their…

This study looked at whether COVID-19 caused more financial hardship for Women of Color compared to other women who decided not to join a breast cancer screening trial. Researchers surveyed 14 women about job loss, income drops, and housing or food insecurity. The goal was to und…

This study tests whether community health forums called WE-CARE can help more rural and low-income women get screened for breast cancer and join clinical trials. The forums include educational sessions, survivor storytelling, and patient navigation to address barriers. Researcher…

This very early trial tested a single dose of HB-201 in 10 people with HPV 16+ throat or cervical cancer. The goal was to see how the drug affects the immune system, not to treat the cancer. The study was terminated early, so results are limited.

This study is testing whether special lab tools—like analyzing tiny particles from blood cells or growing mini-tumors in a dish—can predict how well immunotherapy drugs work in people whose lung cancer has returned. About 40 participants will receive standard immunotherapy drugs …

This early-phase study by AstraZeneca examines how the experimental drug ceralasertib is absorbed, distributed, and eliminated in people with advanced solid tumors. Participants receive the drug orally and a tiny radiolabeled intravenous dose to track its journey. Researchers mea…

This study looked at 10 men to understand why androgen deprivation therapy (ADT) for prostate cancer can lead to high blood pressure. Researchers checked if problems with the nervous system or kidneys were to blame. The goal is to find ways to prevent heart disease in prostate ca…

This study tests whether a moderate-to-vigorous exercise program can change the gut bacteria of people who have survived stage II or III colorectal cancer. Researchers will enroll 30 survivors and randomly assign them to either an exercise group or a health education group. The m…

This study looked at whether providing support for unmet basic needs—like food, housing, or transportation—helps low-income women attend their colposcopy appointment after an abnormal cervical cancer screening. The trial planned to enroll 72 participants but was stopped early wit…

This study is a German national registry that collects information from adults undergoing partial nephrectomy, a surgery to remove kidney tumors while preserving healthy kidney tissue. The goal is to track complications, kidney function after surgery, and survival rates to unders…

This pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…

This study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first t…

This study investigates whether MRI can detect early signs of pancreatic damage linked to obesity and metabolic syndrome, which are risk factors for pancreatic cancer. Researchers will compare MRI images with tissue samples from patients undergoing pancreatic surgery, as well as …

This study investigates how the location of fat tissue in the body—under the skin versus around the organs—affects the function of mitochondria, the energy-producing parts of cells. Researchers will collect small samples of fat tissue from patients undergoing certain abdominal su…

This study is looking at whether tumor biopsies can help predict which patients with melanoma, non-small cell lung cancer, or head and neck cancer will respond to immunotherapy drugs called PD-1 or PD-L1 inhibitors. Researchers will collect tissue samples from about 152 adults be…

This very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…

This study tested an electronic platform called eGAP that helps older cancer patients (65+) complete questionnaires about their health. The goal was to see if the platform was easy to use and practical for patients, caregivers, and doctors. The study was terminated early after en…

This study surveys colorectal cancer patients about their use of complementary and alternative medicines (CAM), such as acupuncture, homeopathy, or dietary supplements. Researchers aim to understand which patients use CAM, why, and how it might affect their quality of life and ca…

This study aimed to find out how often liver fibrosis and cirrhosis occur in people with head and neck cancer, since tobacco and alcohol are risk factors for both. Researchers planned to check liver health using exams and imaging. However, the study was stopped early after only 2…

This study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…

This study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…

This study aimed to see if delaying feeding for a few days after esophageal cancer surgery helps protect muscle mass and improve recovery. It included 239 adults with esophageal cancer who were scheduled for surgery. The study was stopped early, so results are limited.

This study aimed to find out how common antibiotic resistance is in multiple myeloma patients receiving a stem cell transplant. Researchers planned to collect data from 124 adults to help design future studies on preventing infections. The study was stopped early, so results are …

This pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at …

This early-stage study tested whether inhaling the cancer drug afatinib works as well as taking it by mouth. Four healthy adult smokers received both forms in separate sessions to compare drug levels in the blood and lungs. The study was terminated early, so the findings are limi…

This early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter whil…

This study aimed to see if a sensitive molecular test could predict relapse in adults with acute myeloid leukemia (AML) who had a stem cell transplant. Researchers planned to follow 303 patients in remission, comparing outcomes between those with and without detectable disease ma…

This early-phase study tested whether high doses of omeprazole, a common heartburn medication, could safely change certain markers in pancreatic tumors. The trial planned to enroll 25 patients with exocrine pancreatic cancer who were scheduled for surgery. Participants took omepr…

This study looked at how cancer patients experience being rotated horizontally in the Nano-X system. 43 patients completed questionnaires about anxiety and motion sickness before and after rotation. The study was terminated early, so findings are limited.

This study tested whether a web-based screening tool could help monitor depression and distress in adults who had surgery for new head and neck cancer. Participants were randomly assigned to use the tool or receive usual care. The goal was to see if the tool led to more timely me…

This study aimed to see if a simple blood test could predict memory and thinking problems in men with prostate cancer receiving hormone therapy (ADT). Researchers planned to follow 32 men over time, comparing those on ADT to those not on it. The study was stopped early, so result…

This study aimed to see if immune cells in the blood match those inside lung tumors. Researchers hoped to find a simple blood test that could help doctors decide which patients might respond to immunotherapy. The study planned to enroll 22 people with early-stage lung cancer who …

This study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…

This observational study aimed to measure different types of immune cells in women with advanced breast cancer that has spread. Researchers collected blood and leftover tumor samples to see how these cells change over time. The study was terminated early, so only a small number o…

This study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…

This study looked at whether special eye scans (OCT-angiography) can predict how well the remaining kidney will work one year after kidney removal for cancer. Researchers enrolled 30 adults scheduled for total nephrectomy. The goal was to see if retinal blood vessel patterns coul…

This study aimed to find genetic and protein changes in breast cancer that could help predict how the disease behaves. Researchers collected tumor samples from 749 adults with breast cancer and analyzed them for gene activity and mutations. The study was stopped early, so results…

This study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treat…

This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …

This study looked at how radiofrequency ablation (RFA), a procedure that uses heat to destroy tumors, affects the immune system in people with lung metastases from colorectal cancer. Researchers measured immune cells in tumor samples and blood before and after RFA in 20 participa…

This study looked at tiny particles called exosomes in the blood of 172 colorectal cancer patients. Researchers wanted to see if the contents of these particles could help predict survival and cancer spread. The goal was to find new biomarkers that could be measured with a simple…

This study looked at how breast cancer stem cells—cells that can resist treatment and cause cancer to return—emerge during chemotherapy. Researchers collected blood and tumor samples from 56 women before, during, and after treatment to analyze genetic changes. The goal was to und…

This study aimed to find out if patients with metastatic esophageal cancer who were not getting worse after 6 weeks of chemotherapy should continue treatment or stop. It included 15 adults whose cancer had spread and was no longer responding to initial chemo. The study was termin…

This study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was termina…

This study looked at whether the types of bacteria in a person's gut before treatment could predict how well their rectal tumor responds to chemotherapy and radiation. Researchers collected stool samples from 2 patients with stage II or III rectal cancer and compared their gut ba…

This study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …

This study aimed to compare chest X-ray and CT scans for detecting lung metastases in people who had surgery for high-grade soft tissue sarcoma. Only 11 patients were enrolled before the study was terminated early. The goal was to see which method better finds isolated, operable …

This lab study tested two types of human cells to see which could best form a non-stick patch to prevent internal scar tissue after cancer surgery. Researchers collected cells from the peritoneum (lining of the abdomen) and from fat tissue, then grew them in the lab. The study wa…

This study aimed to track quality of life in 52 patients with brain metastases who received radiosurgery (Gamma Knife). Patients filled out questionnaires before treatment and every 3 months for a year. The study was terminated early, so the full impact on daily life remains uncl…

This study looked at whether MRI and PET scans taken two weeks into radiotherapy can predict if cervical cancer will be controlled. Researchers measured tumor size and activity in 9 patients with stage I to IIIB cervical cancer. The goal was to find early signs of treatment failu…

This study looked at why people with mouth or throat cancer wait before seeing a doctor. Researchers interviewed 90 patients and asked them to fill out questionnaires about their feelings, thoughts, and social situation. The goal was to understand what factors cause the delay, so…

This study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing.…

This study aimed to see if a CT scan of the colon (CT-colonography) is more acceptable than a standard colonoscopy for people at high risk of colorectal cancer. It included 39 patients with a personal or family history of advanced polyps or cancer. The main goal was to measure ho…

This study aimed to find the best way to follow up with patients after they finish curative treatment for head and neck cancer. Researchers compared a personalized follow-up schedule, tailored to each patient's needs, with the usual one-size-fits-all approach. The goal was to see…

This study tested whether an online video simulator helps surgeons learn laparoscopic radical prostatectomy, a surgery for prostate cancer. It enrolled 29 surgeons who were new to the procedure, comparing those who used the simulator to those who did not. The trial was terminated…

This study tested a new lab method (RAD51 assay) to see if it could identify ovarian cancer patients whose tumors are vulnerable to the drug olaparib, even if they don't have BRCA gene mutations. The goal was to find a larger group of patients who might benefit from this treatmen…

This study followed 202 bladder cancer patients who were prescribed Adstiladrin (nadofaragene firadenovec) in real-world clinics in the US and Israel. Researchers wanted to see how often the drug led to complete remission and how long that lasted. The study was terminated early, …

This study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…

This pilot study tested a program called SHAREDCare, where a navigator helps lung cancer survivors identify their needs and create a plan to address them. The goal was to improve follow-up care after cancer treatment. However, the study was terminated early and included only 5 pe…

This observational study looked at how much of the immunotherapy drug pembrolizumab stays in the blood of patients with advanced non-small cell lung cancer. Researchers measured drug levels and immune responses in 80 patients receiving pembrolizumab alone or with chemotherapy. Th…

This study looked for new genes that might increase the risk of developing differentiated thyroid cancer. Researchers planned to analyze the complete DNA of people with thyroid cancer and their family members. The study was stopped early and involved 34 participants.

This study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…

This study tested whether ultrasound can reliably show if a critically ill child's stomach is empty before removing their breathing tube. Researchers monitored 34 children in intensive care, scanning their stomachs multiple times over 12 hours after stopping feeding. The goal was…

This study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.

This study looked at how a single round of chemotherapy affects the muscles of women with early-stage breast cancer. Researchers compared three common chemo regimens: paclitaxel alone, paclitaxel plus trastuzumab, and paclitaxel plus carboplatin. They took muscle biopsies and mea…

This study aimed to closely monitor heart function in women with breast cancer receiving common chemotherapy drugs (epirubicin, cyclophosphamide, paclitaxel) to see when heart damage first appears. Researchers planned to use advanced ultrasound and exercise tests to detect early …

This study tested a new planning method to protect areas where dental implants could later be placed in patients receiving radiation for head and neck cancer. Researchers used virtual implant markers on CT scans to adjust radiation doses, aiming to keep implant sites safe without…

This study aimed to see if certain immune cells in the blood could predict which patients with advanced liver cancer would benefit from a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after starting treatm…

This study looked at why some women with breast cancer in Botswana stop taking tamoxifen, a key hormone therapy. Researchers focused on side effects, quality of life, and HIV status. The study was terminated early and only enrolled 10 participants, so findings are limited.

This study aimed to test a simpler consent process to compare three standard chemotherapy regimens for triple-negative breast cancer. Only 2 participants enrolled before the trial was terminated early, so it could not determine which treatment works best. The main goal was to see…

This study aimed to track how soft tissue sarcoma patients feel—symptoms, side effects, and quality of life—when they receive trabectedin chemotherapy again after a break. Only 7 patients were enrolled before the study was stopped early. The goal was to gather real-world patient …

This study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The …

This study looked at whether genetic changes found in urine could match those in tumor tissue for people with high-risk non-muscle invasive bladder cancer. The goal was to see if a urine test could help doctors choose the best immunotherapy for each patient. The study planned to …

This study offered genetic testing to men whose prostate cancer has spread to other parts of the body. Participants provided saliva samples to check for inherited mutations in about 30 cancer-risk genes. The goal was to understand how often these mutations occur and how men feel …

This study aimed to track four bone-related markers in the blood and urine of multiple myeloma patients receiving standard bisphosphonate therapy. Only 3 people enrolled before the study was terminated. It was designed to observe changes over 12 months, not to test a new treatmen…

This study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The m…

This pilot study tested a device called BioTraceIO 360, designed to help doctors plan and monitor procedures that destroy liver tumors using heat. The study planned to enroll 30 people with liver cancer, but only 4 participated before it was stopped early. Researchers looked at w…

This study looked at the safety of the cancer drug nivolumab in people with metastatic kidney cancer who also have kidney failure. Researchers planned to compare side effects in 81 patients with different levels of kidney function. However, the study was terminated early, so the …

This study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metas…

This study looked at whether calcium deposits in breast arteries, seen on mammograms, are linked to heart disease risk factors. Researchers also tested an AI program to automatically detect these calcifications. The goal is to see if routine mammograms could provide extra informa…